Source: International Congress 2014 – Clinical management of interstitial lung diseases and vasculitis
Disease area: Interstitial lung diseases

Abstract

Idiopathic Pulmonary Fibrosis (IPF) is a progressive and fatal disease for which there are no currently effective therapies to improve patient outcomes and slow the progression of the disease. Recent clinical trials provided encouraging data on the use of pirfenidone in patients with mild -to-moderate IPF.Fourteen 14 patients (mean age etc..) with moderate IPF were randomly treated with Pirfenidone + Acetylcysteine (group 1; 7 patients , 4male , mean age 63.3 ± 13 , 2 former-smokers / 5 non-smokers; functional data: FVC 2.14 L ( 59.75 % th ) , DLCO 43% , 6MWT mt 474 ± 115) or with Acetlcysteine alone (group 2; 7 patients, 6 male, mean age 66.1 ± 11 , 3 former-smokers / 4 non-smokers; FVC 1.99 L ( 64.7% th ) , 46% DLCO , 6MWT paths 482 mt ± 138). The patients were followed as outpatients for one year.Results: After 12 months, respiratory functional data documented reduced FVC (-5 and -3 relative percent respectively in group 1 and 2 , chi2 -test p = 0.8), DLCO (-8 and -7 relative percent difference respectively in group 1 and 2, p = 0.9 chi2 -test ) as well as reduced distance walked in meters. (- 45 and -50 m paths respectively in group 1 and 2, chi2 -test p = 0.9 ).Conclusions: Combined therapy with pirfenidone and acetylcysteine in patients with moderate IPF is well tolerated but did not have significant effects on functional outcomes compared with acetylcysteine treatment in monotherapy.

Rating:

Share or cite this content

Citations should be made in the following way:
C. Vitale, M. Lanza, G. Calabrese, G. Caccavo, M. D'Amato, A. A. Stanziola (Naples, Italy). Idiopathic pulmonary fibrosis treatment: Combined pirfenidone + acetylcysteine vs N-acetylcysteine in monotherapy. Eur Respir J 2014; 44: Suppl. 58, 4502

Member's Comments

No comment yet.

Related content which might interest you: Effect of baseline statin use on benefit of nintedanib Source: International Congress 2016 – IPF treatment II Year: 2016 Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 LATE-BREAKING ABSTRACT: Safety and tolerability of N-acetylcysteine (NAC) with pirfenidone in idiopathic pulmonary fibrosis (IPF): PANORAMA Source: International Congress 2015 – Latest developments in clinical studies in acute and chronic lung diseases Year: 2015 Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 Long-term treatment with nintedanib in patients with IPF: An update from INPULSIS®-ON Source: International Congress 2016 – IPF treatment II Year: 2016 Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 High-dose N-acetylcysteine (NAC) in fibrotic interstitial lung diseases, a retrospective analysis Source: Annual Congress 2013 –Diffuse parenchymal lung disease I Year: 2013 Late Breaking Abstract - Pharmacokinetics (PK) of nintedanib with add-on pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): results from INJOURNEY Source: International Congress 2017 – Lung fibrosis: basic science Year: 2017 Tolerance of pirfenidone in Indian patients with idiopathic pulmonary fibrosis – Usual interstial pneumonitis: An initial experience Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis? Year: 2011 Clinical experience with nintedanib for the treatment of IPF in 80 cases Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Safety and efficacy of pirfenidone in patients with lung fibrosis and TERT mutation Source: International Congress 2016 – IPF pathogenesis Year: 2016 LATE-BREAKING ABSTRACT: Detrimental effects of medically indicated oral anticoagulation on survival in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2015 – Latest developments in clinical studies in acute and chronic lung diseases Year: 2015 Long term efficacy of pirfenidone therapy in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – ILDs 3 Year: 2014 Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis Source: Eur Respir J, 52 (2) 1800230; 10.1183/13993003.00230-2018 Year: 2018 Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016 Pirfenidone post-authorization safety registry (PASSPORT) update Source: International Congress 2015 – Treatment of IPF Year: 2015 Effect of anti-acid medication on reduction in FVC decline with nintedanib Source: International Congress 2015 – Treatment of IPF Year: 2015 Effect of baseline composite physiologic index on benefit of nintedanib in IPF Source: International Congress 2016 – IPF treatment I Year: 2016 Inspiration plus: baseline characteristics of the canadian registry for IPF patients on pirfenidone Source: International Congress 2016 – Orphan diseases II Year: 2016 All-case post-marketing surveillance (PMS) of pirfenidone in Japan: Clinical characteristics, efficacy and safety profile in >1300 patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013